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Objective: To examine the relative impact of two chronic neurological disorders, multiple sclerosis and
Parkinson’s disease, by comparing patients’ scores on the medical outcomes study 36-item short form
health survey (SF-36) with the health profile of the United Kingdom population norms.
Methods: 638 people representing the full spectrum of multiple sclerosis and 227 patients with Parkin-
son’s disease were studied. Health status was measured by the SF-36. Scores for the eight health
domains were compared after controlling for age, sex, disease duration, mobility, social class, ethnic-
ity, education, marital status, and employment status.
Results: People with multiple sclerosis and those with Parkinson’s disease had significantly worse
health than the general population on all eight domains measured by the SF-36. The relative impact of
multiple sclerosis and Parkinson’s disease were similar, but multiple sclerosis resulted in poorer scores
on physical functioning and better scores in mental health. People with mild multiple sclerosis who
walked without an aid also had significantly worse scores in all dimensions than the general UK popu-
lation.
Conclusions: The results highlight the need for further research into aspects of health measured by the
SF-36. Nevertheless, generic measures that are applicable across multiple diseases may fail to address
clinically important aspects of the impact of specific disorders.
It is increasingly recognised that health care should beevidence based, and that health care evaluations shouldincorporate the patient’s perspective. This has led to the
development and use of patient based health status rating
scales as outcome measures for clinical trials, audit, and
epidemiological studies. The medical outcomes study 36-item
short form health survey (SF-36)1 is the most widely used
patient based generic measure of health. It generates a profile
of scores for eight health dimensions.
Patient reported health status data from group studies are
valuable as they reflect the impact of disease from the patient’s
perspective. Thus the health profiles of different conditions
can be compared to estimate this relative burden.1 Infor-
mation from such measures could identify areas where
patients are experiencing particular problems, where further
investigation or research is needed, and where clinicians may
be able to offer help. This might eventually mean that services
that meet patients’ needs can be developed on a stronger evi-
dence base.
Several studies have examined health status in multiple
sclerosis2–7 and Parkinson’s disease.8–12 However, as far as we
are aware none has controlled for sociodemographic variables
other than age and sex when making comparisons between
the two disorders or with controls, and most have been in
small samples from a limited population.
This study builds on previous work by examining the
impact of multiple sclerosis and Parkinson’s disease on the
eight health dimensions of the SF-36, in samples of patients
from across the United Kingdom. The health profiles of
patients with multiple sclerosis and Parkinson’s disease were
compared with each other and with UK norms, controlling for
sociodemographic variables. Our aim was to examine the rela-
tive impact of multiple sclerosis and Parkinson’s disease by
comparing them with the health profile of UK norms.
METHODS
Three groups were studied: patients with multiple sclerosis,
patients with Parkinson’s disease, and United Kingdom norms
as a reference group.
Multiple sclerosis
Patients were derived from three separate sources.
Sample 1 was a postal survey of 500 randomly selected and
geographically stratified members of the Multiple Sclerosis
Society of Great Britain and Northern Ireland. This was part of
a larger study developing a patient based outcomemeasure for
multiple sclerosis.13 The SF-36 was administered in a booklet
along with three other health measures and demographic
questions. Non-responders were sent reminders at three and
five weeks.
Sample 2 consisted of adults with clinically definite multiple
sclerosis attending the National Hospital for Neurology and
Neurosurgery in London. Full details of the sampling and the
stratification process for this sample are described
elsewhere.14 Briefly, 150 consecutive attenders were recruited
from a weekly outpatient clinic, from an inpatient neurologi-
cal rehabilitation unit, and from admissions under a single
consultant (AJT).
Sample 3 consisted of adults with clinically definite multiple
sclerosis participating in a study examining the responsive-
ness of a patient based outcome measure for people with mul-
tiple sclerosis. This sample consisted of three subsamples:
patients who were consecutively admitted to the National
Hospital for Neurology and Neurosurgery between February
and November 2000 for rehabilitation (subsample 1) or intra-
venous steroid treatment of relapses (subsample 2); these two
subsamples completed the SF-36 along with other health
measures and demographic questions at time 1 (admission)
and time 2 (discharge for rehabilitation group; six weeks later
for the steroid group). In addition, the questionnaires were
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posted nine months apart to people with a confirmed diagno-
sis of primary progressive multiple sclerosis15 from a clinical
database (subsample 3; n = 119). Non-responders were sent
reminders at three and five weeks. Only the SF-36 scores at
time 1 are used in the present analyses.
In the rehabilitation and steroid subsamples, subjects were
excluded if they appeared to have cognitive impairment
(substantiated by neuropsychological testing) which precluded
reliable completion of questionnaires, if they had other comor-
bid disabling disorders, or if they were not English speaking.
Parkinson’s disease
Data for patients with Parkinson’s disease (n = 227) were
obtained from a population survey of Parkinson’s Disease
Society members. Full details of the sampling and the stratifi-
cation process for this sample are described elsewhere.10
Briefly, the sample was identified from membership of local
branches of the Parkinson’s Disease Society from five areas of
England. Questionnaires were sent to 405 individuals. No
reminders were sent.
United Kingdom norms
The UK population data (n = 2056) were obtained from the
Office of National Statistics Omnibus Survey, archived by the
University of Essex.16 17
Health status assessment
The SF-36 is a widely used generic measure of health status.
Thirty five of the 36 items are grouped into eight scales that
address health constructs considered to be important to most
health care situations: physical functioning, role limitations
(physical problems), bodily pain, general health, vitality, social
functioning, role limitations (emotional problems), and men-
tal health. One item assesses perception of changes in health
but is not used to compute scale scores. Methods for comput-
ing scores, which range from 0 to 100, are reported
elsewhere.1
Statistical analyses
When comparing scores of different samples it is important to
control for variables that might influence the results. Multiple
linear regression analysis is a method for investigating the
extent to which one or more predictive variables (independent
variables) predict an outcome variable (dependent variable). It
is often used to identify whether some critical variable adds
additional predictive value to the predictive equation for a
dependent variable after other independent variables have
already entered the equation.18
We entered the grouping variable (multiple sclerosis v gen-
eral population, Parkinson’s disease v general population, or
multiple sclerosis v Parkinson’s disease) and the socio-
demographic variables in a separate regression equation to
predict each of the SF-36 dimensions. This determined
whether there were significant differences in SF-36 scores
between the groups after controlling for the sociodemographic
variables.
In the comparison of multiple sclerosis patients and the
general population norms, the regression analyses controlled
for social class, ethnicity, education level, sex, marital status,
employment status, and age. Within the multiple sclerosis
sample, subgroup analyses were conducted according to
patients’ level of mobility indoors (walking without aid, walk-
ing with support, using wheelchair). Multiple linear
regression analyses adjusting for age, sex, marital status,
social class, employment, ethnicity, and duration of multiple
sclerosis were used to establish differences in SF-36 scores
between subgroups, and between each of the subgroups and
the general population norms.
In the comparison of Parkinson’s disease patients and general
population norms, age, sex, marital status, social class, and
Table 1 Sample characteristics
Characteristic MS (n (%)) PD (n (%)) UK norms (n (%))
Total number of subjects 638 227 2056
Sex
Female 412 (65) 92 (40) 1122 (55)
Male 219 (35) 135 (60) 929 (45)
Age range
20–39 years 146 (24) 0 (0) 705 (37)
40–59 years 357 (57) 26 (13) 612 (30)
>60 years 118 (19) 196 (87) 644 (33)
Time since diagnosis
0–9 years 309 (51) 137 (63) n/a
10–19 years 200 (33) 59 (27) n/a
>20 years 100 (16) 23 (10) n/a
Ethnicity*
White 464 (96) n/a 1981 (97)
Others 21 (4) n/a 68 (3)
Marital status
Married or with partner 447 (71) 169 (75) 1224 (60)
No 186 (29) 55 (25) 831 (40)
Employment status
Working 144 (24) 2 (1) 1001 (50)
No 482 (76) 222 (99) 994 (50)
Education*
Obtained degree or professional qualification 155 (33) n/a n/a
No 321 (67) n/a n/a
Social class*
Manual social class 185 (41) 90 (50) 940 (48)
No 267 (59) 91 (50) 1032 (52)
Mobility indoors*
Walk unaided 136 (29) n/a n/a
Walk with an aid 204 (43) n/a n/a
Uses wheelchair 130 (28) n/a n/a
*For MS sample, n = 489 (maximum).
MS, multiple sclerosis; n/a, not applicable or not available; PD, Parkinson’s disease.
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employment status were controlled. In the comparison of mul-
tiple sclerosis and Parkinson’s disease patients, age, sex,marital
status, social class, employment, and years since diagnosis of
multiple sclerosis or Parkinson’s disease were controlled.
RESULTS
Sample characteristics
Multiple sclerosis—Completed questionnaires were obtained
from 638 people (sample 1, 288; sample 2, 149; sample 3, 201).
In sample 1 the response rate was 69%; in sample 2, it was 99%
after one person withdrew; in sample 3, four people in the
rehabilitation subsample were excluded because of cognitive
impairment; in the primary progressive cohort, 104 question-
naires were returned, a response rate of 87%.
Parkinson’s disease—Eleven people were subsequently re-
moved from the denominator as they were deceased or did not
have Parkinson’s disease. In all, 227 questionnaires were
returned, a response rate of 57.6%.
The characteristics of the three groups are shown in table 1.
In the multiple sclerosis sample, data for ethnicity, education,
social class, and mobility were available from 489 people as
they were not collected in sample 2. In the Parkinson’s disease
sample, ethnicity, education, and mobility data were not
collected.
There are some expected differences between the three
samples. The multiple sclerosis sample was predominantly
female. The majority of the Parkinson’s disease sample was
aged 60 or over. Although the general UK population included
an equal proportion of those who were employed and unem-
ployed, three quarters of the multiple sclerosis sample and
99% of the Parkinson’s disease sample were not employed.
There were other similarities and differences worthy of note.
The UK norms were younger than the Parkinson’s disease or
multiple sclerosis patients and consisted of fewer married
individuals. The lower response rate for the Parkinson’s
disease patients may have been a result of the absence of
reminders.
Group comparison of SF-36 data
Multiple sclerosis v the general population
Participants with multiple sclerosis had lower mean scores on
all dimensions of the SF-36 compared with the UK norms
after controlling for sociodemographic variables (p < 0.001)
(fig 1). The differences in scores were larger for the two physi-
cal domains of the SF-36 profile: physical function (58 points)
and role limitations–physical (56 points); substantial for five
domains: social function (35 points), role limitations–
emotional (31 points), general health (25 points), vitality (25
points), and bodily pain (21 points); and small for the mental
health dimension (10 points) (fig 1). This indicates that rela-
tive to the UK norms, multiple sclerosis has the greatest
impact on the physical function and role limitations–physical
dimensions. All differences were significant at p < 0.001.
Multiple sclerosis subgroups defined by level of indoor
mobility
Figure 2 compares SF-36 data for three groups defined by
mobility indoors. Less physically disabled individuals had sig-
nificantly higher scores (p < 0.05) on all SF-36 dimensions
than those who used support when walking. Compared with
those who used a wheelchair, those who walked independ-
ently had better scores (p < 0.05) in all dimensions except
role limitations–emotional and mental health dimensions,
where the difference was minimal (differences of 6 points and
5 points, respectively).
A stepwise decrease in scores with disease progression was
seen in the physical function scores. There was a ninefold
decrease in physical function scores between those who
walked independently and those who used a wheelchair (fig
2). The significant floor effect in those who walked with an aid
(14.2%) and those who used wheelchairs (67.8%) may have
led to an underestimation of the differences between these
two groups. A lesser stepwise decrease with disease progres-
sion was seen in social function and general health scores.
Stepwise decreases in scores were not seen in the bodily pain,
vitality, role limitations–emotional, mental health, and role
limitations–physical dimensions. Those who walked with
support scored markedly worse in the role limitations–
physical dimension, with the difference to the “walk without
aid” group being approximately threefold. The three sub-
groups scored similarly on the mental health dimension (69,
62, and 64 points for walk without aid, walk with aid, and
wheelchair groups, respectively).
The SF-36 data for each severity group were compared with
those of the general population (data not shown) and even the
least physically disabled individuals showed a significant
decrease in all dimension scores (p < 0.001). This difference
was greatest for the role limitations–physical (difference of 45
points) and least for the mental health dimension (difference
of 6 points). People who walked with an aid had significantly
lower scores in all dimensions compared with the general
population scores (p < 0.001), and in particular, the role
limitations–physical dimension scores were 66 points lower
than the normal population scores. Wheelchair users also had
lower scores in all dimensions compared with the general
population scores (p < 0.001) and as expected, markedly
lower scores in the physical function dimension (difference of
75 points). Again, the least difference was for the mental
health domain (difference of 9 points).
Figure 1 Graph showing SF-36 scores for multiple sclerosis
patients compared with UK norms controlling for age, sex, marital
status, social class, employment, and ethnicity. Error bars = SEM. BP,
bodily pain; GH, general health perceptions; MH, mental health; PF,
physical functioning; RE, role emotional; RP, role physical; SF, social
functioning; VT, vitality.
Figure 2 Graph showing SF-36 scores for the subgroups of
multiple sclerosis patients controlling for age, sex, marital status,
social class, employment, ethnicity, and years since diagnosis of
multiple sclerosis. Error bars = SEM. BP, bodily pain; GH, general
health perceptions; MH, mental health; PF, physical functioning; RE,
role emotional; RP, role physical; SF, social functioning; VT, vitality.
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Parkinson’s disease v the general population
Participants with Parkinson’s disease also had significantly
lower mean scores for all health dimensions of the SF-36
compared with the UK norms controlling for socio-
demographic variables (p < 0.001) (fig 3). The differences in
profiles were very large for two dimensions: role limitations–
physical (56 points) and role limitations–emotional (51
points); and substantial for six dimensions: physical function
(44 points), social function (35 points), vitality (27 points),
general health (23 points), bodily pain (19 points), and men-
tal health (18 points).
Multiple sclerosis v Parkinson’s disease
The relative impact of multiple sclerosis and Parkinson’s
disease were similar after controlling for duration of illness
and other sociodemographic variables (fig 4). The two disease
groups had similar profiles for role limitations–physical (19
and 18, respectively), bodily pain (54 and 56), general health
(43 and 43), vitality (34 and 35), and social function (49 and
51) (p > 0.05 for all comparisons). However,multiple sclerosis
patients had lower mean scores for physical function
(difference 11 points; p < 0.001) but higher scores for the
mental health dimension (difference 6 points; p < 0.05). The
greatest difference between the two groups was in the role
limitations–emotional dimension, where the multiple sclero-
sis group scored substantially better than the Parkinson’s dis-
ease group (difference 18 points; p < 0.005).
DISCUSSION
In this study we compared the health profile of a large sample
of patients with multiple sclerosis, a smaller sample of
patients with Parkinson’s disease, and the UK norms, control-
ling for multiple sociodemographic variables. In the compari-
son of multiple sclerosis with Parkinson’s disease, disease
duration was also controlled. Results indicate that individuals
with multiple sclerosis and Parkinson’s disease have signifi-
cantly worse health than the general population in all eight
health domains measured by the SF-36. The differences in
profiles of people with multiple sclerosis and the UK norms
were largest in the physical function domain, and smallest in
themental health domain. The differences in profiles of people
with Parkinson’s disease and the UK norms were largest in the
role limitations–physical and smallest in the mental health
and bodily pain domains. Patients with multiple sclerosis and
Parkinson’s disease had similar health profiles in six of the
eight dimensions, but multiple sclerosis resulted in poorer
scores on the physical function and better scores in the men-
tal health domain.
Subgroup analyses showed consistent health profiles across
groups, but also provided some useful insights into the impact
of multiple sclerosis. Even people who walk without an aid,
and therefore might be viewed as having milder disease, had
significantly worse scores in all dimensions compared with
the general UK population. But the dramatic stepwise
decrease in physical function scores as a result of increasing
disability was not accompanied by a stepwise decrease in
other health dimensions. Indeed, the differences in the
subgroup profiles tended to be smallest for the mental health
dimension. The most impaired group in the role limitations–
physical dimension was comprised of patients who required
support for walking.Wheelchair users had better scores in role
limitations–physical, vitality, role limitations–emotional, and
mental health than people who needed an aid for walking.
In multiple sclerosis, the results from this UK sample sup-
port the findings of studies from Canada3 and Norway.2 The
Norwegian study also found that the relative impact of multi-
ple sclerosis was least for the mental health dimension. The
Canadian study showed that significant impacts in all SF-36
dimensions were seen in patients with low expanded disabil-
ity status scores (less physical disability), and those with less
impairment of ambulation. Our results build on these studies.
A large sample of multiple sclerosis patients was recruited
from diverse clinical settings (community, inpatient rehabili-
tation, and inpatient steroids for multiple sclerosis relapses)
and we controlled for multiple sociodemographic variables.
These factors improve the general applicability of the results.
In Parkinson’s disease, the results support the findings of
two other studies in the United Kingdom.8 10 Schrag et al used
a sample of Parkinson’s disease patients from a population
based prevalence study and compared it with published qual-
ity of life (QoL) norms for the UK population.8 They found
worse QoL scores in all areas except pain. In contrast, we
showed a significant impact on pain. In the current study, after
controlling for multiple sociodemographic variables in our
comparisons with the general population scores, individuals
with Parkinson’s disease had poorer scores on all dimensions
of QoL. Finally, as far as we are aware this is the first study to
show similarities and differences between multiple sclerosis
and Parkinson’s disease, two chronic progressive disabling
neurological disorders, by systematically controlling for
potential confounding variables. However, in contrast to the
multiple sclerosis patients, who were recruited from diverse
settings, the Parkinson’s disease sample was recruited solely
from the community. This, and the low response rate in that
sample, suggests that the sample may not have been fully
representative—a specific weakness of our study.
The relatively similar mental health scores (compared with
scores for other dimensions) between multiple sclerosis
Figure 3 Graph showing SF-36 scores for patients with Parkinson’s
disease compared with UK norms controlling for age, sex, marital
status, social class, and employment. Error bars = SEM. BP, bodily
pain; GH, general health perceptions; MH, mental health; PF,
physical functioning; RE, role emotional; RP, role physical; SF, social
functioning; VT, vitality.
Figure 4 Graph showing SF-36 scores for multiple sclerosis
patients compared with Parkinson’s disease patients, controlling for
age, sex, marital status, social class, employment, and years since
diagnosis of multiple sclerosis or Parkinson’s disease. Error bars =
SEM. BP, bodily pain; GH, general health perceptions; MH, mental
health; PF, physical functioning; RE, role emotional; RP, role
physical; SF, social functioning; VT, vitality.
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patients and the general UK population contrasts with
published reports and clinical experience. Further analyses
(available from the authors) showed that this result is
consistent even when steroid treated patients are excluded
from the analyses. Clinical experience suggests that multiple
sclerosis is associated with substantial psychological
distress.19 20 One interpretation of our finding is that in our
study, people with multiple sclerosis had adapted to the
psychological demands of the illness. Another interpretation
is that the SF-36 mental health dimension has limited validity
as a measure of mental health in multiple sclerosis. Evidence
in support of the latter interpretation comes from the finding
that the SF-36mental summary score (which incorporates the
mental health scale) underestimates the impact of multiple
sclerosis on mental health.21 Furthermore, the correlation
between the SF-36 mental health and the psychological
impact scale of the multiple sclerosis impact scale (MSIS-29),
a disease specific measure developed from people with multi-
ple sclerosis, is 0.76.13 This indicates that the constructs
measured by these two scales are related but distinct, and far
from identical (they have less than 60% shared variance). This
finding highlights the fundamental importance of reliable and
valid health measurements for evidence based medicine.
It is important to note that the SF-36 is not a needs assess-
ment tool. It simply highlights areas of health impact that
require further investigation for specific management. The
results from our study support the need for further research
(including the assessment of health care needs) that is sensi-
tive to at least the eight constructs measured by the SF-36. In
multiple sclerosis in particular, results suggest that this should
include patients in the early stage of the disease. Further
research could identify how patients cope, what their unmet
needs are, and how clinicians might meet these needs (if that
is indeed possible) and what services might be developed to
support them in doing so.
Conclusions
Measures of health status, such as the SF-36, can detect areas
of disease impact that may not be obvious from the clinical
situation. This information, supplemented by further investi-
gations such as the assessment of health care needs, is capable
of guiding subsequent disease intervention. However, it is
important to recognise that generic measures may fail to
address clinically important aspects of the impact of a specific
disease, and cross sectional studies do not define change in
disease impact over time. Studies are required to determine
the specific domains of health affected by diseases, as well as
the natural history of the impact of neurological disorders on
health status.
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